Skip to Content

ProtoKinetix Inc PKTX

Morningstar Rating
$0.01 0.00 (5.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PKTX is trading at a 830% premium.
Price
$0.01
Fair Value
$4.18
Uncertainty
Extreme
1-Star Price
$4.64
5-Star Price
$5.73
Economic Moat
Xdkt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PKTX is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.03
Bid/Ask
$0.00 / $0.27
Market Cap
$4.85 Mil
Volume/Avg
325,981 / 119,126

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees

Valuation

Metric
PKTX
Price/Earnings (Normalized)
Price/Book Value
12.94
Price/Sales
Price/Cash Flow
Price/Earnings
PKTX

Financial Strength

Metric
PKTX
Quick Ratio
0.04
Current Ratio
0.06
Interest Coverage
Quick Ratio
PKTX

Profitability

Metric
PKTX
Return on Assets (Normalized)
−86.79%
Return on Equity (Normalized)
−94.63%
Return on Invested Capital (Normalized)
−94.63%
Return on Assets
PKTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBdlxcjczGhx$605.7 Bil
VRTX
Vertex Pharmaceuticals IncWssdypwvlRbymf$116.3 Bil
REGN
Regeneron Pharmaceuticals IncYzqllkycNgglnt$108.5 Bil
MRNA
Moderna IncPqyptxlwLwqc$62.9 Bil
BNTX
BioNTech SE ADRXmsvfrkrMkyj$23.9 Bil
ARGX
argenx SE ADRXhzrtvpjJsgs$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncHynvfhsgNbyvcjv$18.9 Bil
BMRN
Biomarin Pharmaceutical IncDbjzzccsQwsxkq$14.3 Bil
INCY
Incyte CorpVnxrshpSxmlwy$12.9 Bil
UTHR
United Therapeutics CorpQnzmlljPjm$12.1 Bil

Sponsor Center